CJC-1295

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Clinical research has demonstrated that a single injection can increase GH levels by 2- to 10-fold for six or more days and elevate IGF-1 levels by 1.5- to 3-fold for 9–11 days.¹ Popular among anti-aging enthusiasts, bodybuilders, and athletes seeking enhanced recovery and body composition, CJC-1295 is typically administered at doses ranging from 100–300 mcg (without DAC) daily or 300–1000 mcg (with DAC) once or twice weekly. Most users report noticeable effects within 4–12 weeks of consistent use.

What Is CJC-1295?

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone that functions as a GHRH analog. It was developed by ConjuChem Biotechnologies and designed to overcome the primary limitation of natural GHRH—its extremely short half-life of approximately 7 minutes in circulation.²

The peptide exists in two primary forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF). The DAC modification allows the peptide to covalently bind to serum albumin after injection, extending its half-life to 5.8–8.1 days.¹ Without DAC, the half-life is approximately 30 minutes, which more closely mimics the body's natural pulsatile GH release pattern.

What makes CJC-1295 unique among growth hormone secretagogues is its ability to produce sustained, dose-dependent increases in both GH and IGF-1 without significantly altering other pituitary hormones such as prolactin, FSH, LH, or TSH.¹ This selectivity distinguishes it from direct GH administration and offers a more physiological approach to enhancing the GH/IGF-1 axis.

Primary human-use benefits reported by users and observed in research include:

• Increased lean muscle mass and strength
• Enhanced fat metabolism and body composition
• Improved recovery from exercise and injury
• Better sleep quality
• Potential anti-aging effects through elevated IGF-1 levels
• Increased collagen synthesis and skin elasticity

How It Works

GHRH Receptor Activation

CJC-1295 mimics the action of endogenous growth hormone-releasing hormone by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland.³ When the peptide binds to these receptors, it triggers a signaling cascade that stimulates the synthesis and secretion of growth hormone. This mechanism preserves the body's natural feedback systems, unlike exogenous GH administration which can suppress endogenous production.

Extended Half-Life Through Albumin Binding

The DAC technology represents a significant pharmacological advancement. After subcutaneous injection, CJC-1295 with DAC forms a covalent bond with circulating albumin through a reactive maleimido group.² This bioconjugation protects the peptide from enzymatic degradation and renal clearance, extending its biological activity from minutes to days. Research published in the Journal of Clinical Endocrinology & Metabolism confirmed an estimated half-life of 5.8–8.1 days in healthy adults.¹

Pulsatile vs. Sustained GH Release

CJC-1295 without DAC produces a more pulsatile pattern of GH release, which some researchers believe better mimics natural physiology. The body normally releases GH in pulses, with the largest occurring during deep sleep. CJC-1295 with DAC creates more sustained elevation of GH and IGF-1 levels, which may be advantageous for certain therapeutic applications but could potentially blunt the natural pulsatile rhythm.⁴

IGF-1 Axis Activation

Beyond direct GH stimulation, CJC-1295 activates the broader GH/IGF-1 axis. Elevated GH stimulates the liver to produce IGF-1, which mediates many of growth hormone's anabolic effects on muscle, bone, and other tissues.⁵ Clinical trials demonstrated that IGF-1 levels remained elevated above baseline for up to 28 days following multiple doses of CJC-1295.¹

Dosage Protocols

CJC-1295 without DAC (Mod GRF 1-29):

• Typical dose: 100–300 mcg per injection
• Frequency: 1–3 times daily
• Timing: Often administered before bed to coincide with natural GH release, and/or upon waking and post-workout
• Cycle length: 8–12 weeks, followed by 4 weeks off

CJC-1295 with DAC:

• Starting dose: 300 mcg per injection twice weekly
• Maintenance dose: 600–1000 mcg once or twice weekly
• Some protocols suggest gradual dose escalation, increasing by approximately 250 mcg every 2 weeks as tolerated⁶
• Cycle length: 8–12 weeks

Cycling Guidelines:
Most practitioners recommend cycling CJC-1295 to prevent receptor desensitization and maintain the body's responsiveness to the peptide. A common approach involves 8–12 weeks on, followed by 4–8 weeks off. Some users employ a "5 days on, 2 days off" weekly schedule with the non-DAC version to preserve pulsatile release patterns.

How to Use / Administration

CJC-1295 is administered via subcutaneous injection, typically into the abdominal fat, thigh, or upper arm. The injection process involves:

1. Reconstitution (detailed below)
2. Drawing the appropriate dose using an insulin syringe (typically 29–31 gauge)
3. Cleaning the injection site with an alcohol swab
4. Pinching the skin and inserting the needle at a 45-degree angle
5. Injecting slowly and withdrawing the needle
6. Rotating injection sites to prevent lipodystrophy

For CJC-1295 without DAC, many users inject 2–3 times daily—upon waking, post-workout, and before bed. The pre-sleep dose is considered particularly important as it coincides with the body's natural nocturnal GH surge.

For CJC-1295 with DAC, once or twice weekly injections are sufficient due to the extended half-life. Consistency in timing (e.g., every Monday and Thursday) helps maintain stable blood levels.

Results Timelines

Weeks 1–2: Most users report improved sleep quality and more vivid dreams. Some experience mild water retention and increased appetite.

Weeks 2–4: Enhanced recovery from workouts becomes noticeable. Some users report improved skin quality and minor fat loss.

Weeks 4–8: More significant changes in body composition typically emerge, including increased muscle fullness and continued fat reduction. Strength gains may become apparent.

Weeks 8–12: Cumulative effects peak, with users often reporting the most dramatic improvements in lean mass, recovery, and overall body composition. Clinical research supports this timeline, showing that IGF-1 levels remained elevated above baseline for up to 28 days with repeated dosing, suggesting cumulative benefits.¹

Individual responses vary considerably based on age, baseline GH levels, diet, training, and sleep quality.

Research Evidence

The most significant clinical study on CJC-1295 was published in the Journal of Clinical Endocrinology & Metabolism in 2006. This randomized, placebo-controlled, double-blind trial examined the pharmacokinetics, pharmacodynamics, and safety of CJC-1295 in healthy adults aged 21–61 years.¹

Key findings included:

• Single injections produced dose-dependent increases in GH concentrations of 2- to 10-fold lasting 6 or more days
• IGF-1 levels increased 1.5- to 3-fold for 9–11 days after a single dose
• Multiple doses produced cumulative effects, with IGF-1 remaining elevated above baseline for up to 28 days
• No serious adverse reactions were reported
• The peptide was "safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg"

Animal research published in the American Journal of Physiology demonstrated that once-daily administration of CJC-1295 normalized growth in GH-deficient models, supporting its potential therapeutic applications.⁷

A 2009 study in Growth Hormone & IGF Research further confirmed the activation of the GH/IGF-1 axis by CJC-1295, establishing its efficacy as a long-acting GHRH analog.⁵

It should be noted that a Phase II clinical trial investigating CJC-1295 for HIV-associated lipodystrophy was halted in 2006 following a patient death, though the relationship to the study drug was not definitively established.⁸

Stacking

CJC-1295 is frequently combined with other peptides to enhance its effects:

CJC-1295 + Ipamorelin: This is the most popular combination. Ipamorelin is a growth hormone secretagogue that works through the ghrelin receptor, providing a complementary mechanism to CJC-1295's GHRH pathway. Together, they produce synergistic GH release greater than either peptide alone.⁹ Typical dosing involves 100–300 mcg of each peptide administered together.

CJC-1295 + GHRP-6 or GHRP-2: These growth hormone-releasing peptides also work through the ghrelin pathway and can be stacked with CJC-1295. GHRP-6 notably increases appetite, which may be beneficial for those seeking to gain mass.

CJC-1295 + BPC-157: Some users combine CJC-1295 with BPC-157 for enhanced recovery and healing, though this combination lacks clinical research.

When stacking, users typically reduce individual peptide doses slightly to account for synergistic effects and minimize potential side effects.

Reconstitution, Storage & Prep

CJC-1295 is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use.

Reconstitution Process:

1. Allow the peptide vial to reach room temperature
2. Using bacteriostatic water (preferred) or sterile water, slowly inject the diluent down the inside wall of the vial—never directly onto the powder
3. Gently swirl the vial until the powder is fully dissolved; do not shake vigorously
4. For a 2mg vial, adding 2ml of bacteriostatic water creates a concentration of 1mg/ml (1000 mcg/ml), making dosing calculations straightforward

Storage:

• Unreconstituted powder: Store in a cool, dry place; refrigeration extends shelf life to 24+ months
• Reconstituted solution: Must be refrigerated at 2–8°C (36–46°F)
• With bacteriostatic water: Stable for approximately 4–6 weeks refrigerated
• With sterile water: Use within 5–7 days
• Never freeze reconstituted peptides
• Protect from light

Side Effects

Clinical trials reported that CJC-1295 was generally well-tolerated, with no serious adverse reactions at therapeutic doses.¹ However, users commonly report:

Common side effects:

• Injection site reactions (redness, pain, swelling)
• Flushing and warmth, particularly facial flushing lasting 5–10 minutes post-injection
• Water retention
• Headaches
• Dizziness
• Increased hunger
• Tingling or numbness in extremities
• Fatigue or lethargy initially

Less common side effects:

• Nausea
• Joint discomfort
• Mood changes
• Anxiety
• Flu-like symptoms

Potential concerns:
The FDA has noted concerns about increased heart rate and cardiac events associated with CJC-1295.¹⁰ Individuals with active cancer, cardiovascular disease, or diabetes should exercise particular caution, as elevated GH and IGF-1 can theoretically promote cell proliferation and affect glucose metabolism.

Legal Status / FDA

CJC-1295 is not FDA-approved for human use. In the United States, it exists in a regulatory gray area—it can be legally purchased for "research purposes only" but is not approved for human consumption or medical treatment.

In December 2024, the FDA's Pharmacy Compounding Advisory Committee discussed CJC-1295 among other peptides, with the agency expressing concerns about cardiac risks and the potential for peptide impurities in compounded preparations.¹⁰ The FDA has moved to restrict compounding pharmacies from producing certain peptides, including CJC-1295, citing safety concerns and lack of adequate clinical data.

Internationally, regulations vary significantly. Some countries permit peptide sales with fewer restrictions, while others classify them as controlled substances.

Sports/WADA

CJC-1295 is explicitly prohibited by the World Anti-Doping Agency (WADA). It appears on the Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) as a growth hormone-releasing factor.¹¹

The WADA Prohibited List specifically names "growth hormone-releasing hormone (GHRH) and its analogues (e.g., CJC-1295, sermorelin and tesamorelin)" as banned substances at all times, both in and out of competition.¹²

Athletes subject to anti-doping testing should be aware that CJC-1295 and its metabolites can be detected in urine samples. Research published in Drug Testing and Analysis has established methods for identifying CJC-1295 in biological samples.¹³

Conclusion

CJC-1295 represents a significant advancement in growth hormone secretagogue technology, offering a method to enhance the body's natural GH production rather than replacing it with exogenous hormone. Clinical research has demonstrated its ability to produce sustained, dose-dependent increases in both GH and IGF-1 levels with a favorable safety profile at therapeutic doses.

For individuals who choose to use CJC-1295, understanding proper dosing, administration, and cycling protocols is essential for optimizing results while minimizing risks. The peptide's effects on body composition, recovery, and overall well-being have made it popular among those seeking alternatives to direct GH therapy.

However, users must acknowledge the regulatory landscape: CJC-1295 is not FDA-approved, is prohibited in competitive sports, and carries potential risks that warrant careful consideration. As with any peptide or hormone-modulating compound, consultation with a knowledgeable healthcare provider is advisable.

FAQ

What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 5.8–8.1 days due to its ability to bind to albumin, requiring only once or twice weekly injections. CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes, requiring multiple daily injections but producing a more natural pulsatile GH release pattern.

How long does it take to see results from CJC-1295?
Most users report improved sleep within 1–2 weeks. Noticeable changes in body composition, recovery, and muscle fullness typically emerge between weeks 4–8, with peak effects occurring around weeks 8–12 of consistent use.

Can CJC-1295 be used for anti-aging purposes?
Many users employ CJC-1295 for its potential anti-aging benefits, as elevated GH and IGF-1 levels are associated with improved skin quality, body composition, and recovery. However, long-term safety data for this application is limited.

Is CJC-1295 detectable in drug tests?
Yes. WADA-accredited laboratories can detect CJC-1295 and its metabolites in urine samples. Athletes subject to anti-doping testing should not use this peptide.

What happens if I miss a dose?
For CJC-1295 with DAC, simply resume your regular schedule—do not double dose. For CJC-1295 without DAC, missing occasional doses is less significant due to the frequent dosing schedule; simply continue with your next planned injection.

Can women use CJC-1295?
Yes. CJC-1295 does not directly affect sex hormones and can be used by women. Dosing is typically similar to that used by men, though some women start at the lower end of the dosing range.

Should CJC-1295 be taken with food or on an empty stomach?
CJC-1295 is most effective when administered on an empty stomach, as elevated blood sugar and insulin can blunt GH release. Most users inject at least 30 minutes before eating or 2–3 hours after a meal.

What are the signs that CJC-1295 is working?
Early indicators include improved sleep quality, more vivid dreams, and enhanced recovery from exercise. Over time, users may notice increased muscle fullness, fat loss, improved skin quality, and better overall energy levels.

References:

1. Teichman SL, et al. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
2. Jette L, et al. "Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog." Endocrinology. 2005.
3. Wikipedia. "CJC-1295."
4. FDA. "CJC 1295 - Pharmacy Compounding Advisory Committee Materials."
5. Ionescu M, Bhopale G. "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog." Growth Hormone & IGF Research. 2009.
6. Peptide Dosages. "CJC 1295 DAC (5mg Vial) Dosage Protocol."
7. Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology-Endocrinology and Metabolism. 2006.
8. Aidsmap. "Lipodystrophy study halted after patient death." 2006.
9. Innerbody. "CJC-1295 + Ipamorelin | Benefits, Safety & Buying Advice."
10. Hone Health. "Everything You Need to Know About the FDA Peptide Ban."
11. Thomas A, et al. "Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation." Drug Testing and Analysis. 2011.
12. WADA. "2024 Prohibited List - International Standard."
13. PubMed. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295."